LimeLight of The week is

Lexaria Bioscience Corp.
(NASDAQ: LEXX)

Lexaria Bioscience Corp. (NASDAQ: LEXX) is a global innovator in drug delivery platforms. The company’s patented technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules. DehydraTECH promotes fast-acting, less expensive and more effective oral drug delivery and has been thoroughly evaluated through in vivo, in vitro and human clinical testing.

DehydraTECH is covered by 25 issued and more than 50 pending patents in over 40 countries around the world. Lexaria’s first patent was issued by the U.S. Patent and Trademark Office in October 2016 (US 9,474,725 B1), providing 20 years of patent protection expiring June 2034. Multiple patents have been awarded since then and are expected in the future.

Lexaria has a collaborative research agreement with the National Research Council (NRC), the Canadian government’s premier research and technology organization. The company has filed for patent protection for specific delivery of nicotine, vitamins, NSAIDs, testosterone, estrogen, cannabinoids, terpenes, PDE5 inhibitors (with brand names like Viagra), tobacco and more.

Lexaria began developing DehydraTECH in 2014 and has since continued to strengthen and broaden the technology. The company has no plans to create or sell Lexaria-branded products containing controlled substances. Instead, Lexaria licenses its technology to other companies around the world to offer consumers the best possible performance across an array of ingestible product formats.

The company’s technology is best thought of as an additional layer that providers of consumer supplements, prescription and non-prescription drugs, nicotine and CBD products can utilize to improve the effectiveness of their own existing or planned new offerings. Lexaria has licensed DehydraTECH to multiple companies, including a world-leading tobacco producer for the research and development of smokeless, oral-based nicotine products, and for use in industries that produce cannabinoid beverages, edibles and oral products.

DehydraTECH is suitable for use with a wide range of product formats including pharmaceuticals, nutraceuticals, consumer packaged goods and over-the-counter capsules, pills, tablets and oral suspensions. the property, and taking key steps toward delivering on the promise of Sugarmade’s farm-to-door vision.”

Investment Considerations

• Lexaria Bioscience Corp. has disruptive proprietary technology protected by a broad international patent portfolio.
• The company has been issued 25 patents in the U.S., European Union and other countries, with more than 50 patents pending around the world.
• Lexaria’s DehydraTECH technology has a vast worldwide, multi-billion-dollar total addressable market, including multiple rapid-growth segments like cannabinoid and noncombustible nicotine delivery.
• The company has licensed its fat-soluble active molecule delivery technology to multiple established companies for use in their products.
• Lexaria completed an uplisting to Nasdaq Capital Markets and an $11 million financing in January 2021.

Recent Coverage

Lexaria Bioscience Corp. (NASDAQ: LEXX) Leveraging Growing Commercial Opportunities

May 27, 2022 9:00 AM

• Lexaria is a biotechnology company focused on licensing its proprietary DehydraTECH(TM) technology
• The DehydraTECH technology has been proven to increase the bioavailability, speed of onset and brain absorption of APIs, and improve customer experiences by masking unwanted tastes
• Lexaria has 25 patents granted worldwide and is pursuing numerous other pending patent applications
• The company operates several subsidiary companies to focus on different commercial opportunities

Ever since acquiring its first intellectual property (“IP”) that subsequently formed the basis of its first two patent application filings in 2014, biotechnology company Lexaria Bioscience (NASDAQ: LEXX) has grown the number of patents granted and patent applications exponentially, with 25 patents granted worldwide as of April 2022. The latest patent, the 10th granted in the United States, represents the first-ever patent for the use of DehydraTECH(TM) drug delivery technology in the enhanced delivery of antiviral drugs. Described by CEO Chris Bunka as “another validation of the versatility of our DehydraTECH drug technology,” the award of the IP protection marks a key step toward the ultimate monetization of DehydraTECH, according to an April 21 news release (https://cnw.fm/q8zmr).

To view the full source article, visit: THIS LINK

Receive SMS Text Alerts from CannabisNewsWire

Text "Cannabis" to 844-397-5787

(US Mobile Phones Only)

Featured Event

CWCBExpo
June 2 – 4, 2022 – New York City | Javits Convention Center

Move your business and career forward in the fastest growing East Coast business sector at CWCBExpo New York. CWCBExpo events are the leading B2B trade shows and conferences for the cannabis, CBD and hemp industries. Connect in-person and learn from world-renowned experts. Meet with leading exhibitors and find the latest products, technologies, and services while networking and forming new business collaborations. Only at CWCBExpo. In New York.

The CWCBExpo Conference Program Delivers Quality.
In Conversation With... Tremaine Wright, Chair of the Cannabis Control Board

Tremaine Wright, Chair, New York State Cannabis Control Board; Gia Morón, President Women Grow, Founder and CEO, GVM Communications

Add-on Workshop Master Session:
Dispensaries: The Rising Green Sun

With the wave of legalization across the USA for medical cannabis and adult-use cannabis, owning a dispensary has become a desirable goal for many as it can be quite lucrative. This workshop goes through the entire real-life experience of owning a dispensary. Attendees will hear from east and west coast dispensary owners, retailers, and designers about owning and maintaining a dispensary. This Workshop Master Session will cover the following topics:

• Dispensary competition landscape
• Zen of picking the optimal location & design for retail
• Staffing a dispensary
• Financials of maintaining a dispensary
• Safety & security
• Optimizing the consumer Experience
• Future of dispensary ownership
• Q&A

Conference Highlights

• Attendees experience the potential of the market through educational sessions, innovative product displays, elite networking opportunities, and much much more – all while sourcing the next big opportunity. CWCBExpo is where cannabis and hemp business gets done.
• Capitalize on the vast market potential of the New York tri-state area and elevate your company to the highest position within the cannabis business community. As an exhibitor, you’ll meet other business people and have opportunities to collaborate with top providers.  As an attendee you will find a full array of cannabis and hemp related services that you can utilize and invest in.  Our exhibitor list is growing fast, so check back often.
• CWCBExpo offers a multitude of opportunities to promote your products and build your business. From increasing brand awareness to driving traffic to your booth to gaining recognition as an industry expert and getting front and center with the media, CWCBExpo brings you an array of opportunities and sponsorship packages to meet and exceed your sales and marketing objectives.

Upcoming Events

• O’Cannabiz Toronto — Toronto — 6/1 - 6/3
• NECANN’s Vermont Convention — Essex, VT — 6/11 - 6/12
• Grow Up Conference — Victoria, BC — 6/20 - 6/22

About CannabisNewsWire (CNW)

CannabisNewsWire (CNW) is a multifaceted financial news and publishing company that delivers a new generation of social communication solutions, news aggregation and syndication, and enhanced news release services. Leveraging a professional team of journalists and writers, CNW introduces private and public companies to a wide audience of investors, consumers, journalists and the general public via social media and a rapidly expanding network of over 5,000 key distribution outlets. Cutting through information overload, CNW's innovative and proprietary systems clearly and succinctly deliver its clients much needed visibility, recognition and brand awareness. CNW is where news, content and information converge.